Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

NAPLEX 2022 > TRADITIONAL CHEMOTHERAPY AGENT SPECIFICS > Flashcards

TRADITIONAL CHEMOTHERAPY AGENT SPECIFICS Flashcards

1
Q

WHICH CHEMO CLASSES ARE CELL CYCLE INDEPENDENT AGENTS

A

ALKYLATING AGENTS
PLATINUM-BASED COMPOUNDS
ANTHRACYCLINES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

WHICH AGENTS ARE IN THE ALKYLATING AGENTS CLASS?

A

CYCLOPHOSPHAMIDE, IFOSFAMIDE
CARMUSTINE, LOMUSTINE
BUSULFAN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

WHICH AGENTS ARE PLATINUM BASED COMPOUNDS?

A

CISPLATIN
CARBOPLATIN
OXALIPLATIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

WHICH ARENTS ARE ANTHRACYCLINES

A

DOXORUBICIN, DAUNORUBICIN
MITOXANTRONE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

WHICH CHEMO CLASSES ARE CELL CYCLE SPECIFIC AGENTS

A

TOPOISOMERASE INHIBITORS (1 AND 2)
VINCA ALKALOIDS
TAXANES
PYRIMIDINE ANALOG ANTIMETABOLITES
FOLATE ANTIMETABOLITES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ALKYLATING AGENT MOA

A

CROSS LINKING DNA STRANDS, INHIBITING PROTEIN SYNTHESIS AND DNA SYNTHESIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HOW DOES MESNA WORK

A

INACTIVATES TOXIC METABOLITE ACROLEIN THAT CONCENTRATES IN THE BLADDER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

WHAT IS THE TOXIC METABOLITE OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE

A

ACROLEIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PLATINUM BASED COMPOUNDS MOA

A

CROSS LINK DNA, INHIBITING DNA SYNTHESIS AND CELL REPLICATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PLATINUM BASED COMPOUND WARNING

A

PLATINUM COMPONENT CAN CAUSE TOXICITIES RELATED TO HEAVY EMTAL POISONING, LIKE NEUROPATHY, OTOTOXICITY, AND NEPHROPATHY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CARBOPLATIN CALVERT FORMULA

A

USED TO CALCULATE DOSE FOR TARGET AUC
DOSE = (TARGET AUC)X(GFR+25)
AUC CAN RANGE FROM 2-8
GFR IS CAPPED AT 125

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PLATINUM BASED COMPOUND BOXED WARNING

A

ANAPHYLACTIC LIKE REACTIONS
RISK INCREASES WITH REPEATED EXPOSURE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

WHICH ANTHRACYCLINES HAVE A UNIQUE COLOR

A

DOXORUBICIN IS RED
MITOCANTRONE IS BLUE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TOPOISOMERASE 1 INHIBITOR INHIBITS WHICH PHASE

A

S PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TOPIOSOMERASE 2 INHIBITORS INHIBIT WHICH PHASE

A

BLOCK G2 PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

VINCA ALKALOIDS MOA
WHICH PHASE?

A

INHIBIT FUNCTION OF MICROTUBULES IN M PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

VINCA ALKALOIDS THAT ARE ASSOCIATED WITH MORE BONE MARROW SUPPRESSION THAN VINCRISTINE

A

VINBLASTINE AND VINOREBLINE
BOTH HAVE B IN NAME

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

TAXANES MOA AND PHASE

A

INHIBIT FUNCTION OF MICROTUBULES IN M PHASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TAXANE BOXED WARNING

A

INFUSION RELATED HYPERSENSITIVITY REACTIONS AND FATAL ANAPHYLAXIS WITH ALL TAXANES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TAXANE DRUG INTERACTION WITH ANOTHER CHEMO CLASS

A

TAXANE ELIMINATION REDUCED WHEN GIVE AFTER CISPLATIN/CARBOPLATIN
GIVE TAXANES BEFORE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

WHICH TAXANE DOES NOT CAUSE HYPERSENSITIVITY AND DOES NOT NEED PREMEDICATION

A

PACLITAXEL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PYRIMIDINE ANALOG ANTIMETABOLITES MOA AND PHASE

A

INHIBIT PSYRIMIDINE SYNTHESIS DURING S PHASE

23
Q

WHAT METABOLITES IS INCORPORATED INTO RNA WHEN PYRIMIDINE ANALOGS ARE USED

A

F-UMP
S-dUMP

24
Q

FOLATE ANTIMETABOLITE MOA AND PHASE

A

INTERFERE WITH ENZYMES INVOLVED IN FOLIC ACID CYCLE, BLOCKING PURINE AND PYRIMIDINE SYNTHESIS DURING S PHASE

25
HOW IS DOSING DIFFERENT FOR METHOTREXATE IN RA/PSORIASIS VS ONCOLOGY
DOSES IS MUCH HIGHER IN ONCOLOGY RA/PSORIASIS DOSES ARE WEEKLY DOSES
26
WHAT IS ADMINISTERED TO ↓ RISK OF NEPHROTOXICITY WITH METHOTREXATE
HYDRATION AND IV NA-BICARB TO ALKALINIZE THE URINE
27
IF WANT TO USE SUPPLEMENTS TO ↓ RISK OF SIDE EFFECTS WITH FOLATE ANTIMETABOLITES, WHICH ONES ARE USED?
A REDUCED FORM OF FOLIC ACID IS NEEDED (REGULAR FOLATE DOES NOT WORK)
28
WHICH MEDICATIONS CAN INTERACT WITH METHOTREXATE
NSAIDS SALICYLATES
29
WHICH mTOR AGENTS CAN BE USED IN ONCOLOGY
EVEROLIMUS TEMSIROLIMUS
30
EVEROLIMUS SIDE EFFECTS
MOUTH ULCERS/STOMATITIS RASH INTERSTITIAL LUNG DISEASE PERIPHERAL EDEMA DYSLIPIDEMIA ↑BP
31
BEVACIZUMAB MOA
VEGF INHIBITOR
32
VEGF INHIBITOR CONCERNS
IMPAIRS WOUND HEALING - DO NOT GIVE 28 DAYS BEFORE OR AFTER SURGERY SEVERE/FATAL BLEEDING GI PERFORATION
33
TRASTUZUMAB MOA
HER2 INHIBITOR
34
HER2 INHIBITOR CONCERNS
MONITOR LVEF DUE TO RISK OF HF
35
CETUXIMAB MOA
EGFR INHIBITOR
36
EGFR INHIBITOR PHARMACOGENOMICS
FOR LUNG CANCER MUST BE KRAS WILD TYPE TO USE MUTATION PREDICTS POOR RESPONSE
37
EGFR INHIBITOR CONCERNS
ACNEIFORM RASH RASH INDICATES BETTER RESPONSE TO DRUG AVOID SUNLIGHT USE EMOLLIENTS, STEROIDS, ABX TO REDUCE SKIN DAMAGE
38
RITUXIMAB MOA
LEUKOCYTE CLUSTER OF DIFFERENTIATION (CD) ANTIGEN INHIBITOR
39
CD-INHIBITOR CONCERNS
PREMEDICATE WITH BENADRYLL, APAP, STEROID DUE TO RISK OF INFUSION REACTIONS
40
PROGRAMMED DEATH RECEPTOR-1 (PD-1) INHIBITOR CONCERNS
IMMUNE-MEDIATED TOXICITIES
41
CYTOTOXIC T-LYMPHOCYTE ANTIGEN-4 (CTLA-4) INHIBITOR CONCERN
REMS PROGRAM FATAL IMMUNE MEDIATED REACTION
42
WHAT TESTING SHOULD BE DONE BEFORE ADMINISTERING TKIs
PHARMACOGENOMIC TESTING TO IDENTIFY PATIENTS WHO WILL BENEFIT
43
IMATINIB USE AND MOA
CHRONIC MYELOGENOUS LEUKEMIA (CML) BCR-ABL INHIBITOR
44
IMATINIB CONCERNS
MUST BE BCR-ABL POSITIVE TO USE CAN CAUSE FLUID RETENTION AND EDEMA
45
BRAF INHIBITOR USE
USED IN MELANOMA
46
BRAF INHIBITOR CONCERNS
MUST BE BRAF V600E OR V600K MUTATION POSITIVE NEW MALIGNANCIES CAN OCCUR
47
MITOGEN-ACTIVATED EXTRACELLULAR KINASE (MEK) 1 AND 2 INHIBITOR CONCERNS
USED IN COMBINATION WITH BRAF INHIBITORS IN PATIENTS WITH BRAF V600E AND V600K MUTATIONS
48
EGFR INHIBITOR USE
NON-SMALL CELL LUNG CANCER (NSCLC)
49
EGFR INHIBITOR CONCERNS
MUST BE EGFR MUTATION POSITIVE RASH THAT INDICATES A BETTER RESPONSE
50
ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS USE
NON-SMALL CELL LUNG CANCER (NSCLC)
51
ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS CONCERNS
MUST BE ALK MUTATION POSITIVE
52
COMMON TOXICITIES WITH TKIs
THYROID GLAND (HYPOTHYROIDISM) HEART (QT PRLONGATION) SKIN (RASH) BLOOD VESSELS (HTN, HAND AND FOOT SYNDROME) LIVER (HEPATOTOXICITY) INTESTINES (DIARRHEA)
53
WHICH ORAL CHEMO AGENTS SHOULD BE GIVEN WITH FOOD
IMATINIB CAPECITABINE
54
WHICH ORAL CHEMO AGENTS CAN BE TAKEN WITHOUT REGARD TO FOOD
ANASTRAZOLE TAMOXIFEN

NAPLEX 2022 (37 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions